Progress for Alzheimer’s researchers
A Shanghai-based research group yesterday announced progress in developing a drug to treat Alzheimer’s disease.
GV-971 was developed by Ocean University of China, Shanghai Institute of Materia Medica under the Chinese Academy of Sciences and Green Valley Pharmaceutical Co, after a 21-year study.
A phase three clinical trial is the last test before reaching the market.
Extracted from brown algae, the drug is targeted at patients with mild-to-moderate Alzheimer’s. Independent animal experiments also showed it can regulate the immune system, reduce neuro-inflammation and improve cognition.
Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory, thinking skills, and the ability to carry out simple tasks. The disease affects about 48 million people worldwide, and the number is expected to increase with the aging population.
- About Us
- |
- Terms of Use
- |
- RSS
- |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证:沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证:31120180004
- |
- 网络视听许可证:0909346
- |
- 广播电视节目制作许可证:沪字第354号
- |
- 增值电信业务经营许可证:沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.